Search
Pradaxa® (dabigatran etexilate) Overview Factsheet
bi-aff-act-eeo-stmts (2)
BI-TermsCondQualtrics.pdf
Breaking-Down-Biosimilars-Infographic.pdf
BIAH Corporate Booklet A5 Update
Glyxambi-LongForm.pdf
biah-us-overview-for-usda
BIPI Post Marketing Requirements PDF | Boehringer Ingelheim US
PAP Eligibility Information
Benefits Overview (BIPI)
Benefits Overview (BIUSA)
Paid time off Policy BIPI
BIFellowshipBrochure 24-26
BI_asthma_infographic.pdf
Biotherapeutics Modalities Infographic
bi-aff-act-eeo-stmts (2)
BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US
The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.
ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US
American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund
FDA approves additional formulation of biosimilar
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
Research & Development Video | BI Careers
Prof. Eric Haaksma speaks about his career and the Boehringer Ingelheim mission to transform lives for generations.
Accessibility Statement
Accessibility Statement
Rafal Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
Results for Jardiance® (empaglifozin) | BI US
Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.
USDA & BI Expand Research Opportunities | Boehringer Ingelheim US
Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.